Public-Private Route to Covid Drugs Holds Promise Post-Pandemic

June 16, 2021, 7:15 PM

Putting industry and academic eyes together to spot the most promising Covid-19 treatments offered a fresh approach to tackling disease that the NIH director wants to stick around once the pandemic subsides.

The National Institutes of Health created a public-private partnership called ACTIV to coordinate the development of Covid-19 treatments and vaccines in April 2020. The partnership whittled about 600 potential treatments down to 40 and ultimately pursued about a dozen that had the best chance of working, NIH Director Francis Collins said Wednesday.

“We did try to have a very regularized rigorous way to do the priority setting and ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.